Apotea AB AI Stock Analysis
Want to see SE:APOTEA full AI Analyst Report?
Apotea AB (APOTEA) AI Stock Analysis
Apotea AB
(Nasdaq OMX AB:APOTEA)
The overall score is heavily driven by Apotea's fundamentally sound financial health, highlighted by excellent return on equity, consistent revenue expansion, and low leverage. Exceptional upward price trends provide strong technical support, though investors should be aware that the elevated valuation multiple relies on continued high growth.
Apotea AB (APOTEA) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 10.45B
- Dividend Yield
- 0.60%
- Average Volume (3M)
- 241.10K
- Price to Earnings (P/E)
- 40.5
- Beta (1Y)
- 0.39
- Revenue Growth
- 10.25%
- EPS Growth
- -1.52%
- Country
- Sweden
- Employees
- 736
- Sector
- General
- Sector Strength
- 55
- Industry
- Specialty Retail
Apotea AB Business Overview & Revenue Model
Company Description
Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair...
How the Company Makes Money
Apotea makes money primarily by selling products directly to consumers via its online channels. Key revenue streams include: (1) Prescription medicines: revenue from dispensing prescription drugs ordered through Sweden’s e-prescription system and ful...
Apotea AB Financial Statement Overview
Summary
Apotea AB exhibits a robust financial foundation characterized by steady revenue growth, expanding EBITDA margins, and a highly conservative debt-to-equity ratio of 0.29. An exceptional return on equity of 35.2% highlights efficient capital use, strongly offsetting minor weaknesses related to cash flow volatility.
Income Statement
86Very PositiveBalance Sheet
88Very PositiveCash Flow
75Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.81B | 7.20B | 6.54B | 5.45B | 4.88B | 4.56B |
| Gross Profit | 2.10B | 1.94B | 1.79B | 1.45B | 1.27B | 750.33M |
| EBITDA | 553.80M | 464.10M | 399.60M | 226.00M | 104.80M | 183.77M |
| Net Income | 258.70M | 228.70M | 214.90M | 87.00M | 19.90M | 104.49M |
Balance Sheet | ||||||
| Total Assets | 2.14B | 1.98B | 146.49M | 132.18M | 1.25B | 1.02B |
| Cash, Cash Equivalents and Short-Term Investments | 110.70M | 3.31M | 2.46M | 1.89M | 18.20M | 81.38M |
| Total Debt | 263.40M | 331.00M | 21.78M | 25.89M | 332.70M | 144.33M |
| Total Liabilities | 1.09B | 1.12B | 89.25M | 90.14M | 897.50M | 684.99M |
| Stockholders Equity | 1.03B | 844.00M | 55.37M | 39.93M | 327.50M | 339.76M |
Cash Flow | ||||||
| Free Cash Flow | 132.50M | 117.70M | 42.40M | 94.70M | -110.60M | 145.82M |
| Operating Cash Flow | 150.40M | 333.30M | 206.20M | 215.80M | 31.50M | 227.30M |
| Investing Cash Flow | -17.90M | -214.50M | -163.70M | -121.60M | -141.40M | -81.58M |
| Financing Cash Flow | -120.00M | -115.30M | -34.20M | -93.30M | 46.30M | -78.39M |
Apotea AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:APOTEA, the sentiment is Positive. The current price of 100.40 is above the 20-day moving average (MA) of 95.84, above the 50-day MA of 87.43, and above the 200-day MA of 73.63, indicating a bullish trend. The MACD of 4.48 indicates Negative momentum. The RSI at 65.15 is Neutral, neither overbought nor oversold. The STOCH value of 57.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:APOTEA.
Apotea AB Peers Comparison
Overall Rating
SE:CLAS.B78Outperform
SE:APOTEA76Outperform
SE:RUSTA61Neutral
SE:DSNO59.2Neutral
SE:CDON58Neutral
SE:KJELL45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | SEK 35.50B | 28.11 | 41.64% | 1.88% | 9.82% | 33.55% | |
| 76Outperform | SEK 10.48B | 40.48 | ― | 0.60% | 10.25% | -1.52% | |
| 61Neutral | SEK 12.26B | 20.69 | ― | 2.25% | 8.20% | 40.01% | |
| 59Neutral | SEK 126.17M | -44.31 | -2.54% | ― | -8.90% | 67.39% | |
| 58Neutral | SEK 495.43M | -6.21 | ― | ― | 7.12% | 8.47% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 45Neutral | SEK 1.74B | -50.01 | -2.25% | ― | -2.34% | 93.68% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:APOTEA | Apotea AB | 100.40 | 14.07 | 16.29% | |
| SE:CLAS.B | Clas Ohlson AB | 558.50 | 215.37 | 62.77% | |
| SE:DSNO | Desenio Group AB | 0.13 | 0.06 | 80.28% | |
| SE:KJELL | Kjell Group AB | 18.20 | 10.37 | 132.56% | |
| SE:RUSTA | Rusta AB | 79.85 | 15.43 | 23.96% | |
| SE:CDON | CDON AB | 44.00 | -21.00 | -32.31% |
Apotea AB Corporate Events
Apotea reports stronger growth and improved profitability
Apotea reported third-quarter revenue of SEK 1,990.4 million, up 12.5% year on year, while operating profit rose to SEK 107.4 million and the EBIT margin improved to 5.4%. Profit for the period increased to SEK 81.8 million, although gross margin eas...
Apotea Sets Date for Q3 2026 Report and Investor Webcast
Apotea AB will publish its third-quarter 2026 report on 5 November at 07:30 CEST and follow up with a webcast presentation at 09:30 CEST the same day. The interim results for January to September 2026 will be presented in English by CEO Pär Svärdson,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
